Myocholine (Bethanechol Chloride)

Bethanechol is a direct agonist of muscarinic (M3) receptors. By binding to these receptors on smooth‑muscle cells, it increases intracellular calcium, leading to contraction of the detrusor muscle in the bladder and enhanced peristalsis in the intestines, thereby promoting urinary and gastrointestinal motility.

The dose of Myocholine is individualized by the prescribing clinician based on the patient’s age, renal function, severity of the condition, and response to therapy. No fixed regimen is provided here; the prescriber will set the appropriate dosage and schedule.

Safety data for Bethanechol in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Myocholine product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myocholine (Bethanechol) is a direct muscarinic agonist, whereas other agents such as anticholinesterases increase acetylcholine levels indirectly. Bethanechol’s effect is more predictable because it is not degraded by acetylcholinesterase, but it may cause more cholinergic side effects. Choice of therapy depends on patient tolerance, comorbidities and clinician preference.

Store Myocholine at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Myocholine is taken orally as a tablet. It should be swallowed whole with a glass of water, usually on an empty stomach unless otherwise directed by the prescriber. The exact timing relative to meals is determined by the treating physician.

Serious adverse events include bradycardia, severe hypotension, and bronchospasm, especially in patients with underlying cardiac or respiratory conditions. Prompt medical evaluation is required if these symptoms occur, as they may indicate a potentially life‑threatening reaction.

Myocholine is contraindicated in patients with known hypersensitivity to Bethanechol, severe asthma, obstructive urinary tract disease, uncontrolled hypertension, or recent myocardial infarction. It should also be used with caution in individuals with renal impairment, elderly patients, and those taking interacting medications.